← FDA Drug Approvals (Drugs@FDA)

CRENESSITY

NDA · New Drug Application · Sponsor: NEUROCRINE · Approved 2024-12-13

Drug application

FDA Application #

NDA218808

Application type

New Drug Application

Brand name

CRENESSITY

Generic name

CRINECERFONT

Active ingredients

CRINECERFONT

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

NEUROCRINE

Manufacturer

Neurocrine Biosciences, Inc.

First approval

2024-12-13

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown